IBDEI2K0 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40772,2)
 ;;=^5015877
 ;;^UTILITY(U,$J,358.3,40773,0)
 ;;=R30.0^^152^2016^36
 ;;^UTILITY(U,$J,358.3,40773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40773,1,3,0)
 ;;=3^Dysuria
 ;;^UTILITY(U,$J,358.3,40773,1,4,0)
 ;;=4^R30.0
 ;;^UTILITY(U,$J,358.3,40773,2)
 ;;=^5019322
 ;;^UTILITY(U,$J,358.3,40774,0)
 ;;=N92.1^^152^2016^39
 ;;^UTILITY(U,$J,358.3,40774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40774,1,3,0)
 ;;=3^Excessive/Frequent Menstruation w/ Irregular Cycle
 ;;^UTILITY(U,$J,358.3,40774,1,4,0)
 ;;=4^N92.1
 ;;^UTILITY(U,$J,358.3,40774,2)
 ;;=^5015909
 ;;^UTILITY(U,$J,358.3,40775,0)
 ;;=Z08.^^152^2016^41
 ;;^UTILITY(U,$J,358.3,40775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40775,1,3,0)
 ;;=3^F/U Exam After Malig Neop Treatment
 ;;^UTILITY(U,$J,358.3,40775,1,4,0)
 ;;=4^Z08.
 ;;^UTILITY(U,$J,358.3,40775,2)
 ;;=^5062667
 ;;^UTILITY(U,$J,358.3,40776,0)
 ;;=Z80.3^^152^2016^42
 ;;^UTILITY(U,$J,358.3,40776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40776,1,3,0)
 ;;=3^Family Hx of Breast CA
 ;;^UTILITY(U,$J,358.3,40776,1,4,0)
 ;;=4^Z80.3
 ;;^UTILITY(U,$J,358.3,40776,2)
 ;;=^5063347
 ;;^UTILITY(U,$J,358.3,40777,0)
 ;;=Z80.49^^152^2016^43
 ;;^UTILITY(U,$J,358.3,40777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40777,1,3,0)
 ;;=3^Family Hx of Genital Organ CA
 ;;^UTILITY(U,$J,358.3,40777,1,4,0)
 ;;=4^Z80.49
 ;;^UTILITY(U,$J,358.3,40777,2)
 ;;=^5063351
 ;;^UTILITY(U,$J,358.3,40778,0)
 ;;=Z80.41^^152^2016^44
 ;;^UTILITY(U,$J,358.3,40778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40778,1,3,0)
 ;;=3^Family Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,40778,1,4,0)
 ;;=4^Z80.41
 ;;^UTILITY(U,$J,358.3,40778,2)
 ;;=^5063348
 ;;^UTILITY(U,$J,358.3,40779,0)
 ;;=N73.9^^152^2016^47
 ;;^UTILITY(U,$J,358.3,40779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40779,1,3,0)
 ;;=3^Female Pelvic Inflammatory Disease,Unspec
 ;;^UTILITY(U,$J,358.3,40779,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,40779,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,40780,0)
 ;;=N60.32^^152^2016^48
 ;;^UTILITY(U,$J,358.3,40780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40780,1,3,0)
 ;;=3^Fibrosclerosis,Left Breast
 ;;^UTILITY(U,$J,358.3,40780,1,4,0)
 ;;=4^N60.32
 ;;^UTILITY(U,$J,358.3,40780,2)
 ;;=^5015780
 ;;^UTILITY(U,$J,358.3,40781,0)
 ;;=N60.31^^152^2016^49
 ;;^UTILITY(U,$J,358.3,40781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40781,1,3,0)
 ;;=3^Fibrosclerosis,Right Breast
 ;;^UTILITY(U,$J,358.3,40781,1,4,0)
 ;;=4^N60.31
 ;;^UTILITY(U,$J,358.3,40781,2)
 ;;=^5015779
 ;;^UTILITY(U,$J,358.3,40782,0)
 ;;=Z01.411^^152^2016^50
 ;;^UTILITY(U,$J,358.3,40782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40782,1,3,0)
 ;;=3^GYN Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,40782,1,4,0)
 ;;=4^Z01.411
 ;;^UTILITY(U,$J,358.3,40782,2)
 ;;=^5062622
 ;;^UTILITY(U,$J,358.3,40783,0)
 ;;=Z01.419^^152^2016^1
 ;;^UTILITY(U,$J,358.3,40783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40783,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,40783,1,4,0)
 ;;=4^Z01.419
 ;;^UTILITY(U,$J,358.3,40783,2)
 ;;=^5062623
 ;;^UTILITY(U,$J,358.3,40784,0)
 ;;=Z01.419^^152^2016^51
 ;;^UTILITY(U,$J,358.3,40784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40784,1,3,0)
 ;;=3^GYN Exam w/ Normal Findings
 ;;^UTILITY(U,$J,358.3,40784,1,4,0)
 ;;=4^Z01.419
 ;;^UTILITY(U,$J,358.3,40784,2)
 ;;=^5062623
 ;;^UTILITY(U,$J,358.3,40785,0)
 ;;=R87.613^^152^2016^53
 ;;^UTILITY(U,$J,358.3,40785,1,0)
 ;;=^358.31IA^4^2
